Sorafenib alone versus Sorafenib combined with Gemcitabine and Oxaliplatin (GEMOX) in the first-line treatment of advanced hepatocellular carcinoma: final analysis of the randomized phase II GoNext trial (a UNICANCER/FFCD/PRODIGE 10 study)

被引：0
|
作者：
Assenat, E. [1 ]
Boige, V. [2 ]
Thezenas, S. [3 ]
Pageaux, G. P. [4 ]
Perron, J. M. [5 ]
Becouarn, Y. [6 ]
Seitz, J. F. [7 ]
Merle, P. H. [8 ]
Blanc, J. F. [9 ]
Ychou, M. [10 ]
机构：
[1] Univ Hosp Montpellier, Montpellier 05, France
[2] IGR Canc Ctr, Villejuif, France
[3] ICM Canc Ctr, Montpellier, France
[4] CHU St Eloi, Montpellier, France
[5] CHU, Toulouse, France
[6] Inst Bergonier, Bordeaux, France
[7] CHU La Timone, Marseille, France
[8] CHU, Lyon, France
[9] CHU St Andre, Bordeaux, France
[10] ICM Canc Ctr, Montpellier, France
来源：
EUROPEAN JOURNAL OF CANCER | 2013年 / 49卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2467
引用
收藏
页码：S578 / S578
页数：1
相关论文
共 50 条
  • [1] Sorafenib (S) alone versus S combined with gemcitabine and oxaliplatin (GEMOX) in first-line treatment of advanced hepatocellular carcinoma (HCC): Final analysis of the randomized phase II GONEXT trial (UNICANCER/FFCD PRODIGE 10 trial)
    Assenat, Eric
    Boige, Valerie
    Thezenas, Simon
    Pageaux, Georges-Philippe
    Peron, Jean-Marie
    Becouarn, Yves
    Dahan, Laetitia
    Merle, Philippe
    Blanc, Jean-Frederic
    Bouche, Olivier
    Ramdani, Mohamed
    Mazard, Thibault
    Bleuse, Jean-Pierre
    Ychou, Marc
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [2] First-line gemcitabine and oxaliplatin (GEMOX) plus sorafenib, followed by sorafenib as maintenance therapy, for patients with advanced hepatocellular carcinoma: a preliminary study
    Liu, Ying
    Yue, Han
    Xu, Shuning
    Wang, Feng
    Ma, Ning
    Li, Ke
    Qiao, Lei
    Wang, Jufeng
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2015, 20 (05) : 952 - 959
  • [3] First-line gemcitabine and oxaliplatin (GEMOX) plus sorafenib, followed by sorafenib as maintenance therapy, for patients with advanced hepatocellular carcinoma: a preliminary study
    Ying Liu
    Han Yue
    Shuning Xu
    Feng Wang
    Ning Ma
    Ke Li
    Lei Qiao
    Jufeng Wang
    International Journal of Clinical Oncology, 2015, 20 : 952 - 959
  • [4] Sorafenib alone vs. sorafenib plus GEMOX as 1st-line treatment for advanced HCC: the phase II randomised PRODIGE 10 trial
    Assenat, Eric
    Pageaux, Georges-Philippe
    Thezenas, Simon
    Peron, Jean-Marie
    Becouarn, Yves
    Seitz, Jean-Francois
    Merle, Philippe
    Blanc, Jean-Frederic
    Bouche, Olivier
    Ramdani, Mohamed
    Poujol, Sylvain
    de Forges, Helene
    Ychou, Marc
    Boige, Valerie
    BRITISH JOURNAL OF CANCER, 2019, 120 (09) : 896 - 902
  • [5] Sorafenib alone vs. sorafenib plus GEMOX as 1st-line treatment for advanced HCC: the phase II randomised PRODIGE 10 trial
    Eric Assenat
    Georges-Philippe Pageaux
    Simon Thézenas
    Jean-Marie Peron
    Yves Bécouarn
    Jean-François Seitz
    Philippe Merle
    Jean-Frédéric Blanc
    Olivier Bouché
    Mohamed Ramdani
    Sylvain Poujol
    Hélène de Forges
    Marc Ychou
    Valérie Boige
    British Journal of Cancer, 2019, 120 : 896 - 902
  • [6] Randomized phase II trial of first-line treatment with sorafenib versus interferon in patients with advanced renal cell carcinoma: Final results
    Szczylik, C.
    Demkow, T.
    Staehler, M.
    Rolland, F.
    Negrier, S.
    Hutson, T. E.
    Bukowski, R. M.
    Scheuring, U. J.
    Burk, K.
    Escudier, B.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [7] An exploratory subgroup analysis of a phase II/III trial of donafenib versus sorafenib in the first-line treatment of advanced hepatocellular carcinoma
    Bi, F.
    Qin, S.
    Gu, S.
    Bai, Y.
    Chen, Z.
    Wang, Z.
    Ying, J.
    Lu, Y.
    Meng, Z.
    Pan, H.
    Yang, P.
    Zhang, H.
    Chen, X.
    Xu, A.
    Liu, L.
    ANNALS OF ONCOLOGY, 2021, 32 : S820 - S820
  • [8] Phase II study of gemcitabine with oxaliplatin (GEMOX) in heavily treated patients with advanced hepatocellular carcinoma after failure of sorafenib treatment (PEACH)
    Lee, Choong-kun
    Kim, Han Sang
    Choi, Hye Jin
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (04)
  • [9] Randomized phase II trial of sorafenib, capecitabine, and oxaliplatin (SECOX) versus single agent sorafenib in patients with advanced hepatocellular carcinoma.
    Kwok, Gin Wai
    Tang, Vikki
    Leung, Roland Ching-Yu
    Lee, Ann-Shing
    Law, Ada
    Chiu, Joanne Wing Yan
    Li, Bryan
    Cheung, Tan To
    Yau, Thomas
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [10] Randomized phase II trial of sorafenib, capecitabine and oxaliplatin (SECOX) versus single agent sorafenib in patients with advanced hepatocellular carcinoma.
    Yau, Thomas Cheung
    Tang, Vikki
    Leung, Roland Ching-Yu
    Kwok, Gin Wai
    Lee, Ann-Shing
    Law, Ada
    Chiu, Joanne
    Li, Bryan
    Cheung, Tan To
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (04)
12345